“Randomised trials of CABG v PCI are no longer possible & cannot represent real life clinical practice” “Randomised trials of CABG v PCI are no longer.

Slides:



Advertisements
Similar presentations
Is this the “spioenkop” for CABG?
Advertisements

CABG VS Multi Vessel PCI Hasanat Sharif MD FRCS Chief of Cardiorthoracic Surgery Aga Khan University Hospital.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
ARTS I & II Keith D Dawkins Southampton University Hospital.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
C.H.T Dr.Salarifar 1 Tehran Heart Center Tehran University of Medical Sciences PCI VS CABG M. SALARIFAR, MD.
“Randomised trials of CABG v PCI are no longer possible and cannot represent real life practice.” Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Multi-vessel disease and intracoronay physiology Combat MI 2009 Kees-joost Botman MD, PhD Catharina hospital Eindhoven Heart Institute The Netherlands.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Weaknesses of major randomized trials: they are cleverly designed against coronary surgery. They are not representative of the daily practice (highly selected.
Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
U.K. ROLL-OUT OF DRUG-ELUTING STENTS JIM McLENACHAN, YORKSHIRE HEART CENTRE, LEEDS. ADVANCED ANGIOPLASTY 17 th JANUARY, 2003.
Left Main Stem Intervention Trials & Registries Keith D. Dawkins MD FRCP FACC Southampton University Hospital UK.
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
USCV September of 25 The safety and effectiveness of the TAXUS Express2 Stent System have not been established in the following patient.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Multivessel Coronary Artery Disease
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Matching methods for estimating causal effects Danilo Fusco Rome, October 15, 2012.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Revascularization Strategy: Syntax Score and Beyond
Jose M. de la Torre Hernández … in behalf of the 3D investigators
S Ten Tse and Sensibility!
Associate Professor, Honorary Consultant Cardiologist
Randomized vs. Observational Studies: Strengths and Weaknesses
Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital
From: Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery Ann Intern Med.
Disclosure Statement I, Won Ro Lee, hereby acknowledge the AHA’s conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts.
1-year Outcome of The Italian Registry on Chronic Total Occlusion:
Updates From NOTION: The First All-Comer TAVR Trial
A Novel Abluminal Coated Sirolimus-Eluting Stent as a Treatment Option for Diabetic Patients: Results from an All-Comers Multi-center Study: the En-ABL.
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
The MASS-DAC Study.
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
Vladimir Ganyukov, MD, PhD
SYNTAX at 2 Years: This Interventionalist’s Perspective
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
The Syntax Trial: PCI versus CABG
On behalf of J. Belardi, M. Leon, L. Mauri,
The Guidelines Should Be Change!
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
End point Patients >75 y with renal insufficiency
Cardiovacular Research Technologies
Percutaneous coronary invervention versus coronary artery bypass grafting: A meta- analysis  Yolba Smit, MD, MSc, Joan Vlayen, MD, Hetty Koppenaal, MD,
REALITY: 8 month results
Observational Studies vs. Randomized Controlled Trials (RCT)
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.
Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,
Global Registry of Acute Coronary Events: GRACE
Long-term safety and efficacy of zotarolimus-eluting and sirolimus-eluting stents in routine clinical care patients 36-month follow-up in the SORT OUT.
No Financial Disclosure or Conflict of Interest
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Long Term Clinical Results from the Endeavor Program: 5-Year Follow up
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
Atlantic Cardiovascular Patient Outcomes Research Team
Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
Presentation transcript:

“Randomised trials of CABG v PCI are no longer possible & cannot represent real life clinical practice” “Randomised trials of CABG v PCI are no longer possible & cannot represent real life clinical practice” Nick Curzen PhD FRCP FESC Southampton University Hospitals

"If a fight lasts more than 7 seconds then you are doing something wrong………… And it's usually that you are being too soft!" "If a fight lasts more than 7 seconds then you are doing something wrong………… And it's usually that you are being too soft!"

2003 data: Ludman The Current Perception

2003 data: Ludman Mean (Range) 2004 data: Ludman Multi-vessel Treatment All Clinical Presentations The Current Perception

TrialsSingle- or Multi-Vessel n TotalCABGPCIMedical GABIMV EASTMV RITASV & MV ERACIMV CABRIMV BARIMV MASS-2MV AWESOMESV & MV (High risk)* ERACI-2MV SoSMV ARTSMV Stents used Randomised Comparisons of PCI v CABG The Current Perception

“There’s no difference in death or MI between CABG & PCI” “We just need DES to stop restenosis”

The Current Perception

So- the data from RCTs are relevant to our practice then? NO! : are there really no differences in mortality between CABG & PCI in the real world? NO! : are there really no differences in mortality between CABG & PCI in the real world?

No Differences?

Predictors of Mortality Result of Proportional-Hazard Analyses Unadjusted: PCI Covariate adjusted: Renal insufficiency Age in years Previous PCI Insulin-treated diabetes Chronic lung disease Peripheral vasc disease LVEF (  10%) Non-insulin diabetes Angiographic score (  10%) Left main disease Propensity adjusted: PCI PCI BetterCABG Better Circ 2004;109: No Differences?

So- apart from the differences, the data from RCTs are relevant to our practice then? So- apart from the differences, the data from RCTs are relevant to our practice then? NO! : Are the study populations really representative of real life ? NO! : Are the study populations really representative of real life ?

Trial Original Pool Screen 1: Clinical Criteria Screen 2: Physician Agreement Screen 3: Patient ConsentRandomized % Original Pool Randomized GABI EAST RITA 27, ERACI CABRI 42,58023, BARI 25, MASS AWESOME 22, ERACI SoS ~17-30Kn/a998~3-6 ARTSn/a 1205n/a REAL LIFE?

screened!!!! REAL LIFE?

Exclusion Criteria   Previous PCI or CABG   Any total occlusion >1 month old   LVEF<30%   Overt heart failure   H/O CVA   STEMI within 7 days   Diseased saphenous veins REAL LIFE?

Patients Undergoing Angiography 76% do not meet clinical inclusion/exclusion criteria 4% 18% cardiologist & surgeon cannot agree amenable to either revascularization methodology 2% patients will not agree to participate Patient Consent 6% 24% Surgeon & Interventional Cardiologist Agreement Clinical Criteria 100% Randomized REAL LIFE?

So- apart from the differences in mortality in the real world, and the fact that the study populations were not representative of >90% of real life populations, the data from RCTs is relevant to our practice then? NO! : Did the studies really compare complete revascularisation? NO! : Did the studies really compare complete revascularisation?

Maybe the data from these randomised studies aren’t quite so relevant to real life? Maybe the data from these randomised studies aren’t quite so relevant to real life? So……..

?

amenable for only one treatment approach Heart Team (surgeon and interventionalist) Two Registry Arms CABG 2750 captured (750followed) PCI All captured and followed reasonable doubt Goal: to define the most appropriate treatment through randomized trial methods consensus that only one treatment option (CABG vs PCI) is appropriate Goal: to define the pool of non randomizable patients and their outcomes Randomized Arm N=1800 (1:1) amenable for both treatments options TAXUS CABG vs All Patients with 3VD/LM All Comers Design

Overall enrollment are CABG registry!

ConclusionsConclusions “Randomised trials of CABG v PCI are no longer possible because they do not represent >90% of real life clinical practice ” “Randomised trials of CABG v PCI are no longer possible because they do not represent >90% of real life clinical practice ” The extent of CABG registry arm recruitment in SYNTAX so far has already told the common sense cardiologist what he/she needs to know - regardless of the outcome of the randomised group

Acknowledgements Rod Stables Keith Dawkins Boston Scientific Corp M-C Morice Peter Ludman